Argent BioPharma

📌 This article highlights how complex 𝗖𝗡𝗦 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 can be and how nanotherapeutics may pave new paths forward. 📰 Read more: pubs.rsc.org/en/Content/Art… #Nanotechnology #CNS #NeuroImmune #Innovation #Biotech

We are driven by our mission to integrate science, technology, and expertise to proactively combat diseases collaboratively. Learn more on our website: argentbiopharma.com #RGT #Innovation #MedicalResearch

🧠 What is the CNS? According to the Cleveland Clinic, the central nervous system consist of the brain & spinal cord, which control movements, process senses & keep the body running. Read more: my.clevelandclinic.org/health/body/ce… #CNS #NeuroImmune #MedicalResearch #RGT

🧠 This article reports on the multiple factors that drive Alzheimer's—amyloid-β, metal imbalance, enzyme dysregulation, neuroinflammation... That’s why multi-target therapies may hold more promise than single-target ones. 🔗 pubs.rsc.org/en/content/art… #Alzheimers #Innovation #RGT

🔬Our 𝗥&𝗗 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 revolves around understanding the immune system intricacies and embracing the multidiscilinary approach - developing multi-target therapies for 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁. #Pharma #MedicalResearch #Biotech #RGT

💡According to this article, many people with focal epilepsy experience seizures for at least a year after starting treatment as physicians work to find the right drug and dosage. Read more: shorturl.at/sAFK6 #EpilepsyAwareness #Neurology #MedicalResearch #RGT

#Argent is Growing Through M&A: Projected #Merged #Company #Value of $100M in AC8 #Asset #Acquisition tinyurl.com/mmzx7uen @ArgentBioPharma

🌍 Featured in @YahooFinance ! This article reports on our acquisition of AusCann’s core assets as a step toward our planned U.S. national exchange listing. 💪 📰 Read more: finance.yahoo.com/news/argent-gr… #Biotech #PharmaNews #RGT

@StockheadAU reports that in 2025 biotech companies are forging new paths and showing resilience.✨ It’s encouraging to know our company is part of this broader narrative 🚀 📰 Read more: stockhead.com.au/health/biocuri… #Biotech #MarketTrends #PharmaInnovation #PostPandemic #RGT

📰 This article reports that a US in vivo study showed ArtemiC™ achieved 85% survival in a viral inflammatory model — highlighting its potential. Read more: stockhead.com.au/health/us-in-v… #PreclinicalResearch #ARDS #DrugDevelopment #Biotech #RGT

Independent in vivo study demonstrates up to 85% survival in a viral inflammatory mouse model treated with @ArgentBioPharma's ArtemiC. #ASX #health $RGT stockhead.com.au/health/us-in-v…

🚀 @StocksDownUnder reports that our 𝘀𝗵𝗮𝗿𝗲𝘀 𝗷𝘂𝗺𝗽𝗲𝗱 𝟴𝟲% following the AusCann acquisition, reflecting strong investor confidence. 📰 Read more: stocksdownunder.com/argent-shares-… #Biotech #Investors #MarketNews #RGT

✨ Highlights from Small Caps today ✨ This article covers our acquisition of key assets from AusCann Group and highlights the strengthening of our clinical pipeline and expansion into Europe 🌍. 📰 Read more: smallcaps.com.au/argent-biophar… #PharmaNews #Biotech #RGT

Argent BioPharma (ASX:RGT) has signed a binding term sheet to acquire the key assets and intellectual property of AusCann Group Holdings Ltd. (which was delisted from the ASX in August 2024) in a US$15 million all-share transaction | announcements.asx.com.au/asxpdf/2025081… @ArgentBioPharma $RGT

.@ArgentBioPharma has signed a binding term sheet to acquire the key assets and intellectual property of formerly ASX-listed AusCann Group in a deal worth around US$15 million. #ASX $RGT buff.ly/4hCY73H

🌍 This article states that epilepsy affects 50M people worldwide, with up to 30% living with drug-resistant epilepsy. Since current options can’t provide seizure freedom for these patients, developing new treatments is essential. 🔗 bit.ly/3QOOu9v

🧠 𝗡𝗼𝘁 𝗮𝗹𝗹 𝗲𝗽𝗶𝗹𝗲𝗽𝘀𝘆 𝗿𝗲𝘀𝗽𝗼𝗻𝗱𝘀 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁. This @HopkinsMedicine article explains refractory epilepsy—a form that doesn’t improve with standard meds. 🔗 Learn more: hopkinsmedicine.org/health/conditi… #Epilepsy #RefractoryEpilepsy #HealthEquity

@BofC_Europe reports 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁 in cannabinoid therapies — 𝗳𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗼𝘂𝗿 𝘄𝗼𝗿𝗸 as part of the conversation. 💪 🔗 bit.ly/3WV6DBR #NeuroImmune #PharmaNews #DrugDevelopment

🧠 Promising Results In Treatment-Resistant Epilepsy This @PharmaNowGlobal article highlights a promising case study in the Epilepsy field. It’s rewarding to see our work included in the discourse. 🔗pharmanow.live/latest-news/ca… #Epilepsy #NeuroImmune #Biotech #Research